Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA plus anastrozole versus anastrozole alone in pre-operative HR-positive/HER2-negative early breast cancer
2018-001856-36Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing ATRA plus anastrozole with Anastrozole alone (2 arms). Primary endpoint: Ki67 responder rate. Started Jun 2021; status: terminated.
02
Drugs
tretinoinanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001856-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001856-36.